Regulus Therapeutics Stock News

Regulus Therapeutics Inc. (RGLS) with the stream of 4.85% also noticed, India ECMOHO Limited (MOHO) encountered a rapid change of 0.46% in the last hour of trading session. Regulus Therapeutics The post Traders shouldnt Staggering on this: Regulus Therapeutics Inc. (NASDAQ:RGLS), ECMOHO Limited (NASDAQ:MOHO) appeared first on Stocks Equity .

Geode Capital Management LLC increased its stake in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) by 54.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 589,196 shares of the biopharmaceutical companys stock after purchasing an additional 207,304 shares during the []

Virtu Financial LLC purchased a new stake in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 79,193 shares of the biopharmaceutical companys stock, valued at approximately $64,000. Several other large investors have also recently []

Regulus Therapeutics (NASDAQ:RGLS) and OncoSec Medical (NASDAQ:ONCS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations. Insider & Institutional Ownership 26.3% of Regulus Therapeutics shares are held by institutional investors. Comparatively, []

Definitive Agreement for $34.6 Million in Gross Proceeds LA JOLLA, Calif. , Nov. 24, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the "Company" or "Regulus"), today

Regulus Therapeutics Inc. (NASDAQ:RGLS)s traded shares stood at 1.5 million during the last session, with the companys beta value hitting 2.00. At the close of trading, the stocks price was $0.39, to imply a decrease of -5.85% or -$0.02 in intraday trading. The RGLS shares 52-week high remains $2.32, putting it -494.87% down since that Regulus Therapeutics Inc. (NASDAQ: RGLS) Just Learned Something New After This Weeks -7.94% Loss Read More »

Regulus Therapeutics (NASDAQ:RGLS) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a research note issued to investors on Wednesday, Zacks.com reports. According to Zacks, Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Companys products aim to []

Zacks Investment Research lowered shares of Regulus Therapeutics (NASDAQ:RGLS) from a hold rating to a sell rating in a research note released on Wednesday morning, Zacks.com reports. According to Zacks, Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Companys products aim to treat []

Regulus Therapeutics Inc. (RGLS) CEO Jay Hagan on Q3 2021 Results - Earnings Call Transcript

Regulus (RGLS) delivered earnings and revenue surprises of -42.86% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Nov. 3, 2021 /PRNewswire/ --  Regulus Therapeutics Inc.  (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (

Are these Webull penny stocks to buy or avoid right now? The post 5 Penny Stocks To Buy For Under $1 On Webull Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStock

Last week, the five biggest stock market losers declined between about 36% and 26%. Below is a look at each stock and what they may have in the cards going forward.

The stock price of Regulus Therapeutics Inc (NASDAQ: RGLS) fell over 20% pre-market today. This is why it happened.

SAN DIEGO, Sept. 30, 2021 /PRNewswire/ --  Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs